Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 29;5(1):e006640.
doi: 10.1136/bmjopen-2014-006640.

NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study

Affiliations

NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study

Gwen M C Masclee et al. BMJ Open. .

Abstract

Objectives: Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose aspirin and statins may decrease the risk of oesophageal adenocarcinoma (OAC) among patients with Barrett's oesophagus (BO). However, previous studies did not adequately address bias and confounding. Our objective was to estimate the risk of OAC among patients with BO exposed to NSAIDs, statins and PPIs.

Design: Case-control study nested within a BO cohort.

Setting: Two primary care databases (the UK and the Netherlands (NL)).

Participants: Cases were adults ≥18 years of age with OAC or high-grade dysplasia (HGD) diagnosis ≥1 year after BO diagnosis. Controls were matched on age, sex, year of BO diagnosis and database.

Exposure: Drug use was assessed from BO diagnosis until matching date.

Outcome measure: Adjusted ORs with 95% CI were calculated by conditional logistic regression.

Results: Within the BO cohort (n=15 134), 45 OAC (UK: 40, NL: 5) and 12 HGD cases (NL: 12) were identified. ORa for OAC during NSAID use was 1.2 (95% CI 0.6 to 2.5) and during statin use for >3 years 0.5 (95% CI 0.1 to 1.7). When including HGD cases (n=57), ORa for NSAID use was 0.9 (95% CI 0.5 to 1.8) and for statin use >3 years 0.5 (95% CI 0.1 to 1.7). Higher doses of statins showed lower estimates for OAC and HGD, though not statistically significant. Low-dose aspirin and PPIs did not significantly decrease the risk of OAC and HGD.

Conclusions: In this population-based nested case-control study, use of NSAIDs, PPIs, low-dose aspirin or statins did not reduce the risk of HGD and OAC among patients with BO. These findings indicate that for an unselected group of patients with BO chemoprevention by use of drugs to reduce progression to HGD and OAC should not be directly considered as routine care.

Keywords: EPIDEMIOLOGY.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of Barrett's oesophagus and oesophageal adenocarcinoma cases in the UK and the Netherlands. BO, Barrett's oesophagus; OAC, oesophageal adenocarcinoma; HGD, high-grade dysplasia; THIN, The Health Improvement Network; IPCI, Integrated Primary Care Information; PYs, person years.

Similar articles

Cited by

References

    1. Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med 2014;371:836–45. 10.1056/NEJMra1314704 - DOI - PubMed
    1. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788–97. 10.1111/j.1572-0241.2008.01835.x - DOI - PubMed
    1. Solaymani-Dodaran M, Logan RF, West J. , et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004;53:1070–4. 10.1136/gut.2003.028076 - DOI - PMC - PubMed
    1. de Jonge PJ, van Blankenstein M, Looman CW. , et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010;59:1030–6. 10.1136/gut.2009.176701 - DOI - PubMed
    1. Desai TK, Krishnan K, Samala N. , et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61:970–6. 10.1136/gutjnl-2011-300730 - DOI - PubMed

Substances

Supplementary concepts

LinkOut - more resources